ArticleESMO real world data and digital oncology2026
Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radical cystectomy with neoadjuvant and/or adjuvant therapy is the standard treatment of muscle-invasive urothelial cancer (MIUC). Although perioperative immunotherapy use has expanded, real-world data remain limited. The MINOTAURO study evaluated perioperative treatment patterns and outcomes in Spain. Patients and methods: This retrospective, multicenter study included adults with MIUC treated at 17 hospitals in Northern and Eastern Spain (April 2022-June 2024). Clinical data were extracted from electronic health records. Outcomes included perioperative treatment patterns, pathological response, safety, recurrence, and survival. Overall survival and disease-free survival were estimated using Kaplan-Meier methods. Results: A total of 629 patients were analyzed (median age 71 years; 79.5% male). Most tumors originated in the bladder/urethra (95.0%) and were urothelial (92.8%); 70.4% were clinical stage II. Cisplatin-based neoadjuvant chemotherapy (NAC) was administered to 40% of patients, primarily cisplatin-gemcitabine. The main reasons for not receiving NAC were creatinine clearance <60 mL/min (40.8%), Eastern Cooperative Oncology Group performance status ≥2 (18.4%), and cardiovascular disease (18%). Among NAC-treated patients, 41.3% achieved a pathologically documented complete response, and 50% achieved downstaging. Surgery was carried out in 77% of patients, mainly radical cystectomy. Adjuvant chemotherapy was given to 10.7%, and 46.2% of eligible patients received adjuvant immunotherapy, predominantly nivolumab. Recurrence occurred in 28.9% of patients. At a median follow-up of 18.5 months, 75% were alive and 69.7% were recurrence-free. Conclusions: MINOTAURO demonstrates evolving real-world perioperative management of MIUC, with notable use of perioperative immunotherapy in routine clinical practice and outcomes that appear favorable in comparison with historical data, although no formal comparative analysis was carried out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.